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A case-control study in the Republic of Korea evaluat-
ed the protective effectiveness of the hantavirus vaccine.
Point estimates showed increasing effectiveness with
increasing numbers of doses received: 25% for one dose,
46% for two doses, and 75% for three doses. All 95% con-
fidence intervals overlapped zero; therefore, the findings
could be due to chance.
I
n 1990, the Republic of Korea (ROK) approved a vac-
cine against the Hantaan virus after accepting data that
showed a high seroconversion rate as a surrogate for vac-
cine effectiveness (1). The recommended schedule for vac-
cination is two doses 1 month apart, as a primary
vaccination, and one booster 12 months later. Although the
hantavirus vaccine has been in use since approval, and mil-
lions of doses have been given, the effectiveness of the
vaccine continues to be debated. However, protective
effectiveness of the hantavirus vaccine has been measured
mainly by serologic studies (2–4). 
The Korean Army is one of the largest consumers of the
hantavirus vaccine, second only to public health centers.
Uncertainty about protective effectiveness of the vaccine
has been enhanced by reports on military personnel in
whom hemorrhagic fever with renal syndrome (HFRS)
developed, even though they had received the vaccine.
The ROK Army defines a “high-risk area” for HFRS as
an administrative district where HFRS cases have occurred
during the previous 3 years. Vaccination programs focus
on military units located in these high-risk areas, but vac-
cinating all personnel in those units is impossible because
of budget limitations. Therefore, coverage is not 100%.
In a recent study (4), the authors noted that since a vac-
cination campaign began in 1991, the number of HFRS
patients has decreased significantly (Figure 1). However,
vaccination is likely not the only factor affecting secular
trends in number of HFRS patients; climatic and environ-
mental changes also likely play a role. The present case-
control study was conducted to assess the protective
effectiveness of the hantavirus vaccine. 
The Study
Cases were identified through the hospital-based active
surveillance system of the HFRS maintained by the
Korean Army. Cases occurring from January 1, 2002, to
January 1, 2004, were enrolled prospectively. For early
detection of HFRS, the Korean Army used the operational
clinical criteria to identify cases. Patients with HFRS may
have sudden onset of fever; experience pain in the head,
abdomen, and lower back; and report bloodshot eyes and
blurry vision. Petechiae may appear on the upper body and
soft palate. The patient’s face, chest, abdomen, and back
often appear flushed and red, as if sunburned. Aconfirmed
case of HFRS is defined as a positive result on the high-
density particle agglutination test.
For each case, one control was selected from among the
other patients at each hospital where the case-patient had
been hospitalized. The control was matched with the case-
patient according to unit, age at the time of hospitalization
(±3 years), date of hospitalization (±3 months), and date of
transfer to the present unit (±3 months). If no suitable con-
trol could be found, the intervals around the case-patient’s
unit, age, date of hospitalization and date of transference
were progressively widened until one or more potential
controls were found. For each case-patient, all eligible
controls were listed, and one suitably matched control was
identified at random. As with the case-patients, the final
decisions about each control patient’s eligibility for the
study were made on the basis of a detailed review of hos-
pital records. Decisions about the eligibility of potential
controls were made without knowledge of their vaccina-
tion status.
History of vaccination was sought from vaccination
records kept at each unit. Vaccine had to be received at
least 3 weeks before hospitalization because of the time
required for antibodies to develop and because the incuba-
tion period is ≈3 weeks on average (5). One patient vacci-
nated <3 weeks before hospitalization was excluded from
the data analysis.
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Figure 1. Secular trends in the numbers of hemorrhagic fever with
renal syndrome cases, Republic of Korea (ROK), 1957-1998.Estimates of the relative odds of HFRS associated with
vaccination were estimated by using methods developed
by Mantel and Haenszel (6), which are appropriate for
matched designs. The protective effectiveness of the vac-
cine was estimated as 1 minus the relative odds associated
with vaccine use, times 100. Ninety-five percent confi-
dence limits for the effectiveness were derived from the
95% confidence interval (CI) of the relative odds. Data
were analyzed with SPSS, version 10.0 (SPSS, Inc.,
Chicago, IL).
From January 1, 2002, to January 1, 2004, a total of 57
HFRS cases were identified among troops of the Korean
Army. Of the 57 patients, 3 (5.3%) died. One of three
deaths occurred in previously healthy, vaccinated (first and
second doses) personnel. Twelve, 9, and 2 cases occurred
in personnel who were vaccinated with one, two, and three
doses, respectively. Most cases occurred in October
(15.7%), November (35.7%), and December (17.1%),
although disease also occurred during the spring and the
summer (Figure 2).
Of the 54 persons identified with HFRS from January
2002 to January 2004, those who were vaccinated within 3
weeks of hospitalization were excluded from analysis.
Because the effectiveness was calculated by comparing
each dose (exactly one to three) with no vaccination, case-
patients or controls not applicable to that comparison were
excluded from each matched set. Finally, 41, 38, and 31
matched sets were formed for one, two, and three doses of
the hantavirus vaccine, respectively (Table). Ages of the
case-patients were similar to ages of controls. Estimates of
vaccine effectiveness according to the number of doses
received rose from 25% (95% CI –78% to 68%) for one
dose to 46% (95% CI –35% to 78%) for two doses to 75 %
(95% CI –18% to 95%) for three doses. When recipients
for whom 1 year had passed since their second dose were
excluded, effectiveness of two doses increased markedly
to 70% (95% CI –9% to 92%). 
Conclusions
The results of this study suggest a trend toward protec-
tion for the hantavirus vaccine. The protective effectiveness
of the vaccine strongly depends on the number of doses. In
particular, effectiveness increased when persons for whom
>1 year had passed since their second dose were excluded,
which suggests that the protective effect of the second pri-
mary vaccination does not persist beyond the period recom-
mended for having the booster dose. In addition, we do not
know whether the recommended immunization schedule
was optimal for military personnel and farmers, groups for
whom hantavirus vaccination is recommended. The vacci-
nation schedule should be epidemiologically relevant,
immunologically effective, operationally feasible, and
socially acceptable (7).
In a field study from the former republic of Yugoslavia
conducted by Korean researchers, including the developers
of the hantavirus vaccine (8), no case of HFRS was
observed among 1,900 vaccinees, while 20 confirmed
cases were observed among 2,000 nonvaccinated controls.
Considering that our study showed low protective effec-
tiveness for one or two doses, that no case of HFRS
occurred in Yugoslavian vaccinees before they received
the full three doses was surprising.
Because the case-control studies were not experimen-
tal, they may be subject to biases. The most important
potential biases that might affect this kind of study are
detection and selection bias. If all cases of HFRS were
identified, no detection bias would occur. Because patients
were identified prospectively by active surveillance, we
believe that virtually all cases of HFRS diagnosed during
the study period were identified. Selection bias may occur
when controls do not represent the general population. In
this study, controls were selected randomly from a list of
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Figure 2. Hemorrhagic fever with renal syndrome cases among
Republic of Korea military personnel, by month of onset, January
2002 to January 2004.potentially eligible controls by using a systemic algorithm.
Confounding influences affect the results of a case-control
study if controls differ from case-patients in characteristics
related to risk of contracting the disease and likelihood of
receiving the vaccine. Since the population of this study
consisted of military personnel, bias due to sociodemo-
graphic differences may be negligible. Therefore, other
candidate confounding factors determined by considering
the military milieu were used as matching variables. 
We could not show that vaccine effectiveness estimates
were significant. All of our confidence intervals have
lower bounds less than zero. Therefore, while point esti-
mates show effectiveness, this finding could be due to
chance. Of course, the range of point estimates in studies
with relatively small samples can be wide, and wide confi-
dence intervals that include zero are not uncommon in
many studies on vaccine effectiveness (9). However, cau-
tion is appropriate in interpreting our estimates of vaccine
effectiveness. 
Finally, this study represents a short-term (7.3 months
average) evaluation of protective effectiveness of three
doses of the hantavirus vaccine. To assess the long-term
effectiveness, protection must be monitored over a longer
period.
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